InVitae Corp (NVTA) Announces Earnings Results

InVitae Corp (NASDAQ:NVTA) announced its quarterly earnings results on Tuesday. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.04. The company had revenue of $10.34 million during the quarter, compared to the consensus estimate of $10.90 million. During the same quarter in the prior year, the firm posted ($0.80) earnings per share. The business’s revenue was up 161.1% on a year-over-year basis.

InVitae Corp (NASDAQ:NVTA) traded up 1.24% during trading on Friday, hitting $9.01. 245,338 shares of the company were exchanged. The company’s market capitalization is $381.25 million. The stock’s 50-day moving average is $10.56 and its 200-day moving average is $9.11. InVitae Corp has a 12 month low of $5.76 and a 12 month high of $11.88.

Earnings History for InVitae Corp (NASDAQ:NVTA)

NVTA has been the topic of a number of research reports. Zacks Investment Research upgraded shares of InVitae Corp from a “sell” rating to a “hold” rating in a report on Tuesday, February 14th. Benchmark Co. upgraded shares of InVitae Corp from a “hold” rating to a “buy” rating and boosted their target price for the stock from $8.50 to $11.00 in a report on Tuesday, February 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $12.69.

TRADEMARK VIOLATION NOTICE: This news story was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.chaffeybreeze.com/2017/05/19/invitae-corp-nvta-announces-earnings-results-updated.html.

Several institutional investors have recently added to or reduced their stakes in NVTA. Donald L. Hagan LLC bought a new position in InVitae Corp during the first quarter worth $111,000. Verity Asset Management Inc. bought a new position in InVitae Corp during the first quarter worth $116,000. Nationwide Fund Advisors raised its position in InVitae Corp by 21.1% in the first quarter. Nationwide Fund Advisors now owns 17,121 shares of the medical research company’s stock worth $189,000 after buying an additional 2,987 shares during the period. American International Group Inc. raised its position in InVitae Corp by 31.3% in the first quarter. American International Group Inc. now owns 17,174 shares of the medical research company’s stock worth $190,000 after buying an additional 4,090 shares during the period. Finally, Trexquant Investment LP bought a new position in InVitae Corp during the first quarter worth $200,000.

About InVitae Corp

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

5 Day Chart for NASDAQ:NVTA

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply